CEACAM5 and neoplasm: Regarding tumor markers, elevated CEA and CA19–9 levels were detected in 200 (36.0%) and 61 (11.0%) patients, respectively; these biomarkers are widely used to evaluate tumor burden and disease progression in CRC.